Cancer Genetics, Inc. (NASDAQ:CGIX) Met Earnings 0 times

Cancer Genetics, Inc. (NASDAQ:CGIX) moved up 18% and closed its last trading session at $2.95. This Medical Sector stock currently has the Market Capitalization of 55.7 Million. The Average Volume for the stock is measured as 188.6 Million. The Stock has a 52-Week High of $3.35 and 52-Week Low of $1.1 following the dates, it touched its 52-Week High on Mar 22, 2016 and 52-Week Low on Nov 4, 2016. Currently, the Return on Assets value for the trailing twelve months is -41% with the Return on Equity and Return on Investment of -63.4% and -51.3% respectively. This firm currently has YTD (year to date) performance of 118.52 Percent which is awesome. The Short Ratio for the stock is 5.34.

Cancer Genetics, Inc. (NASDAQ:CGIX) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-1.37. The TTM operating margin is -80.3 percent.

Cancer Genetics, Inc. (NASDAQ:CGIX) reports its Earnings on Thu 23 Mar (In 4 Days). The estimated EPS for the current quarter is said to be $-0.22. Following Earnings result, share price were DOWN 6 times out of last 9 Qtrs. The stock has added about 118.5% since it reported its last earnings. The Closing price of Cancer Genetics, Inc. (NASDAQ:CGIX) at Last Earnings was $1.35 as compared to the previous closing price of $2.5. The Predicted Move on the 7th day after Cancer Genetics, Inc. (NASDAQ:CGIX) will release its earnings at about 12%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Cancer Genetics, Inc. (NASDAQ:CGIX) beats earnings by 75%, The Stock Missed Earnings  3  times and has met earnings  0 times.

Earnings History:

We will discuss the past Quarters Earnings below:

Cancer Genetics, Inc. (NASDAQ:CGIX) reported its previous quarter on 11/10/2016 where it reported the Actual Earnings of $-0.23. The Closing price before the company posted its earnings was $1.35. The Stock surged on the very next day of earnings and maintained its stock price at $1.5 by showing a % change of 11.11 percent from its previous closing price. The Next Day Volume after Earnings was reported as 332013. On the 7th day After Earnings Report, the stock hit its share price as $1.6 by showing 18.52% increase from the Stock price Before Earnings were reported.

On 08/09/2016, the stock reported the EPS of $-0.28 where Analysts were projecting the EPS to be $-0.33 showing a difference of $0.05. Thus Surprise Factor was there with 15.2 percent. Before Earnings Announcement on 08/09/2016, the firm had its stock price of $2.16. And immediately on the next day after earnings announcement, the stock declined -6.02% and closed its trading session at $2.03. On 7th Day after earnings release, Cancer Genetics, Inc. (NASDAQ:CGIX) surged to 7.87% from $2.16 to $2.33.

On 05/10/2016, Analysts were suspecting EPS of $-0.43/share where Cancer Genetics, Inc. (NASDAQ:CGIX) reported its Actual EPS of $-0.39. Thus showing a Surprise of 9.3 percent. The Closing Price of the stock before earnings was $2.59 while on the Next day the stock closed its trading session at $2.31 with a percentage change of -10.81% from the price of 2.59 before Earnings. The Stock Closing Price on the 7th day of earnings was $2.19.

Company Profile:

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biopharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company’s discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, researchers, and academic institutions, as well as biopharma and biotech companies performing clinical trials. The company has a strategic alliance and partnership agreement with ApoCell to work on clinical trial projects that support the liquid biopsy and CTC profiling needs in various trials for targeted therapeutics and immuno-oncology. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.